GlassScriptPhysician profile
Ryan T Trout
NPI 1114594124
$10,932.21
in general payments reported to CMS, 2019-2025
28 companies · $2,999 in 2025
The $2,999 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $703 · 2022: $1,760 · 2023: $1,834 · 2024: $3,636 · 2025: $2,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,002 · Education: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,001.98 |
| Education | $467.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,232.27 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,032.92 | 2021-2025 | Ilumya, Winlevi, Odomzo |
| Galderma Laboratories, L.P. | $963.20 | 2022-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $900.23 | 2022-2025 | Tremfya |
| Genzyme Corporation | $878.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $771.71 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $658.31 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $627.38 | 2023-2024 | Vtama |
| Lilly USA, LLC | $575.07 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $495.48 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $459.06 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $418.99 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $292.43 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $239.05 | 2022 | |
| Leo Pharma INC. | $226.25 | 2021-2025 | Adbry |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $218.36 | 2022-2025 | |
| Amgen INC. | $190.34 | 2023-2025 | Otezla, Otezla |
| Organon LLC | $140.87 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $130.63 | 2024-2025 | Ycanth |
| Almirall LLC | $118.12 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $110.71 | 2024-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $93.19 | 2021 | |
| Epi Health, LLC | $38.13 | 2021-2022 | |
| Biofrontera INC. | $32.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.02 | 2025 | Spevigo |
| Strata Skin Sciences, INC. | $25.32 | 2024 | Xtrac |
| Mayne Pharma Commercial LLC | $24.44 | 2022-2025 | |
| Nabriva Therapeutics, Plc | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Trout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.